Cholangiocarcinoma: Epidemiology, Risk Factors, Pathogenesis, and Diagnosis
Tóm tắt
Từ khóa
Tài liệu tham khảo
Nakeeb A, Pitt HA, Sohn TA, et al.: Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996, 224(4):463–73; discussion 473–5.
Malhi H, Gores GJ: Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 2006, 45(6):856–67.
Patel T: Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001, 33(6):1353–7.
Khan SA, Taylor-Robinson SD, Toledano MB, et al.: Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002, 37(6):806–13.
Strom BL, Hibberd PL, Soper KA, et al.: International variations in epidemiology of cancers of the extrahepatic biliary tract. Cancer Res 1985, 45(10):5165–8.
Carriaga MT, Henson DE: Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer 1995, 75(1 Suppl):171–90.
McLean L, Patel T: Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States. Liver Int 2006, 26(9):1047–53.
Burak K, Angulo P, Pasha TM, et al.: Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004, 99(3):523–6.
Chalasani N, Baluyut A, Ismail A, et al.: Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 2000, 31(1):7–11.
Broome U, Olsson R, Loof L, et al.: Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996, 38(4):610–5.
Parkin DM, Srivatanakul P, Khlat M, et al.: Liver cancer in Thailand. I. A case-control study of cholangiocarcinoma. Int J Cancer 1991, 48(3):323–8.
Chen MF: Peripheral cholangiocarcinoma (cholangiocellular carcinoma): clinical features, diagnosis and treatment. J Gastroenterol Hepatol 1999, 14(12):1144–9.
Soreide K, Soreide JA: Bile duct cyst as precursor to biliary tract cancer. Ann Surg Oncol 2007, 14(3):1200–11.
Tocchi A, Mazzoni G, Liotta G, et al.: Late development of bile duct cancer in patients who had biliary-enteric drainage for benign disease: a follow-up study of more than 1,000 patients. Ann Surg 2001, 234(2):210–4.
Sahani D, Prasad SR, Tannabe KK, et al.: Thorotrast-induced cholangiocarcinoma: case report. Abdom Imaging 2003, 28(1):72–4.
Bond GG, McLaren EA, Sabel FL, et al.: Liver and biliary tract cancer among chemical workers. Am J Ind Med 1990, 18(1):19–24.
Walker NJ, Crockett PW, Nyska A, et al.: Dose-additive carcinogenicity of a defined mixture of “dioxin-like compounds”. Environ Health Perspect 2005, 113(1):43–8.
Sorensen HT, Friis S, Olsen JH, et al.: Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology 1998, 28(4):921–5.
Okuda K, Nakanuma Y, Miyazaki M: Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. J Gastroenterol Hepatol 2002, 17(10):1049–55.
Donato F, Gelatti U, Tagger A, et al.: Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control 2001, 12(10):959–64.
Jaiswal M, LaRusso NF, Gores GJ: Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am J Physiol Gastrointest Liver Physiol 2001, 281(3):G626–34.
Tannapfel A, Benicke M, Katalinic A, et al.: Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 2000, 47(5):721–7.
Su WC, Shiesh SC, Liu HS, et al.: Expression of oncogene products HER2/Neu and Ras and fibrosis-related growth factors bFGF, TGF-beta, and PDGF in bile from biliary malignancies and inflammatory disorders. Dig Dis Sci 2001, 46(7):1387–92.
Furubo S, Harada K, Shimonishi T, et al.: Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma. Histopathology 1999, 35(3):230–40.
Berthiaume EP, Wands J: The molecular pathogenesis of cholangiocarcinoma. Semin Liver Dis 2004, 24(2):127–37.
Jaiswal M, LaRusso NF, Burgart LJ, et al.: Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 2000, 60(1):184–90.
Khan SA, Davidson BR, Goldin R, et al.: Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002, 51 Suppl 6:VI1–9.
Valls C, Guma A, Puig I, et al.: Intrahepatic peripheral cholangiocarcinoma: CT evaluation. Abdom Imaging 2000, 25(5):490–6.
Feydy A, Vilgrain V, Denys A, et al.: Helical CT assessment in hilar cholangiocarcinoma: correlation with surgical and pathologic findings. AJR Am J Roentgenol 1999, 172(1):73–7.
Lee HY, Kim SH, Lee JM, et al.: Preoperative assessment of resectability of hepatic hilar cholangiocarcinoma: combined CT and cholangiography with revised criteria. Radiology 2006, 239(1):113–21.
Manfredi R, Barbaro B, Masselli G, et al.: Magnetic resonance imaging of cholangiocarcinoma. Semin Liver Dis 2004, 24(2):155–64.
Romagnuolo J, Bardou M, Rahme E, et al.: Magnetic resonance cholangiopancreatography: a meta-analysis of test performance in suspected biliary disease. Ann Intern Med 2003, 139(7):547–57.
Fogel EL, de Bellis M, McHenry L, et al.: Effectiveness of a new long cytology brush in the evaluation of malignant biliary obstruction: a prospective study. Gastrointest Endosc 2006, 63(1):71–7.
de Bellis M, Sherman S, Fogel EL, et al.: Tissue sampling at ERCP in suspected malignant biliary strictures (Part 2). Gastrointest Endosc 2002, 56(5):720–30.
Moreno Luna LE, Kipp B, Halling KC, et al.: Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology 2006, 131(4):1064–72.
Shah RJ, Langer DA, Antillon MR, et al.: Cholangioscopy and cholangioscopic forceps biopsy in patients with indeterminate pancreaticobiliary pathology. Clin Gastroenterol Hepatol 2006, 4(2):219–25.
• Chen YK, Pleskow DK: SpyGlass single-operator peroral cholangiopancreatoscopy system for the diagnosis and therapy of bile-duct disorders: a clinical feasibility study (with video). Gastrointest Endosc 2007, 65(6):832–41. This study proved the clinical feasibility of the SpyGlass Direct Visualization System (Boston Scientific) procedure. The procedure provided adequate tissue samples with a good sensitivity to diagnose malignancy.
Fritscher-Ravens A, Broering DC, Knoefel WT, et al.: EUS-guided fine-needle aspiration of suspected hilar cholangiocarcinoma in potentially operable patients with negative brush cytology. Am J Gastroenterol 2004, 99(1):45–51.
Eloubeidi MA, Chen VK, Jhala NC, et al.: Endoscopic ultrasound-guided fine needle aspiration biopsy of suspected cholangiocarcinoma. Clin Gastroenterol Hepatol 2004, 2(3):209–13.
Kluge R, Schmidt F, Caca K, et al.: Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology 2001, 33(5):1029–35.
Anderson CD, Rice MH, Pinson CW, et al.: Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 2004, 8(1):90–7.
Petrowsky H, Wildbrett P, Husarik DB, et al.: Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 2006, 45(1):43–50.
Nakeeb A, Lipsett PA, Lillemoe KD, et al.: Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma. Am J Surg 1996, 171(1):147–52; discussion 152–3.
Patel AH, Harnois DM, Klee GG, et al.: The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000, 95(1):204–7.
Siqueira E, Schoen RE, Silverman W, et al.: Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc 2002, 56(1):40–7.
Levy C, Lymp J, Angulo P, et al.: The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci 2005, 50(9):1734–40.
Akdogan M, Sasmaz N, Kayhan B, et al.: Extraordinarily elevated CA19-9 in benign conditions: a case report and review of the literature. Tumori 2001, 87(5):337–9.